Integrum

Summary of the Rights Issue

• The net proceeds from the Rights Issue will be used for business development and marketing, personnel and operations, R&D and product development, regulatory and clinical investments, operational efficiency and supply chain flexibility, and to ensure financial stability.
• The Rights Issue comprises up to 5,333,582 shares of series B with a subscription price of SEK 8.0 per share. If the Rights Issue is fully subscribed, the Company will receive approximately SEK 42.6 million before deduction of costs related to the Rights Issue.
• Each share, regardless of series, in the Company held on the record date November 13, 2025 entitled the holder to one (1) subscription right. Four (4) subscription rights entitle the holder to subscribe for one (1) new share of series B.
• The last day of trading in the Company's shares including the right to participate in the Rights Issue is November 11, 2025.
• The subscription period will run from and including November 17, 2025, to and including December 1, 2025.
• Trading in subscription rights will take place on Nasdaq First North Growth Market during the period from and including November 17, 2025, to and including November 26, 2025, and trading in paid subscribed shares (BTA) will occur during the period from and including November 17, 2025, to and including December 10, 2025.
• The Rights Issue is covered by subscription commitments and guarantee commitments corresponding to 100 percent of the issue amount. However, the subscription commitments and the guarantee commitments are not secured by bank guarantees, escrow accounts, pledges or similar arrangements.
• No prospectus will be prepared in connection with the Rights Issue. The Company has prepared and published an information document (the "Information Document") in accordance with Article 1.4 db of Regulation (EU) 2017/1129 of the European Parliament and of the Council of 14 June 2017 on the prospectus to be published when securities are offered to the public or admitted to trading on a regulated market, and repealing Directive 2003/71/EC (the "Prospectus Regulation").
• Complete terms and conditions and instructions for the Rights Issue, as well as other information, are set out in the Information Document which has been registered with the Swedish Financial Supervisory Authority (Finansinspektionen) and is available on the Company's website www.integrum.se.

Timetable for the Rights Issue

Advisors

Integrum has engaged DNB Carnegie Investment Bank AB (publ), and Setterwalls Advokatbyrå AB as financial and legal advisers in connection with the Rights Issue.